Memantine in clinical practice - Results of an observational study;Memantin in der klinischen anwendung - Erfahrungen aus der praxis

Psychopharmakotherapie

Volumn 13, Issue 2, 2006, Pages 64-69

  Calabrese, Pasquale ^a,b   Essner, Ute ^a,c   Förstl, Hans ^a,d  

^a Bereich Neuropsychologie ^*

^b ST JOSEF HOSPITAL   (Germany)

^c Lundbeck GmbH   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Alzheimer's disease; Memantine; NMDA receptor antagonist; Observational study

Indexed keywords

MEMANTINE;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL PRACTICE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY;

EID: 33645903541     PISSN: 09446877     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Bickel H. Demenzsyndrom und Alzheimer-Krankheit: Eine Schätzung des Krankenbestandes und der jährlichen Neuerkrankungen in Deutschland. Gesundheitswesen 2000;62:211-8.
2. Danysz W, Parsons CG, Möbius HJ, Stöffler A, et al. Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease - A unified glutamatergic hypothesis on the mechanism of action. Neurotox Res 2000;2:85-97.
3. Danysz W, Parsons CG. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry 2003;18(Suppl 1):S23-32.
4. Davies KL, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;2:1403.
5. Giacobini E. Cholinesterase inhibitors; from the calabar bean to Alzheimer therapy. In: Giacobini E (editor). Cholinesterase inhibitors. London: Martin Duniz, 2000:181-226.
6. Giacobini E. The cholinergic system in Alzheimer disease. Prog Brain Res 1990;84:321-2.
7. th International Conference on Alzheimer's Disease and Related Disorders (ICAD) 2004.
8. Hager K, Calabrese P, Frölich L, Göbel C, et al. An observational clinical study of the efficacy and tolerability of donepezil in the treatment of Alzheimer's disease. Dement Geriatr Cogn Disorder 2003;15:189-98.
9. Han L, Cole M, Bellavance F, McCusker J, et al. Tracking cognitive decline in Alzheimer's disease using the mini-mental state examination: A meta-analysis. Int Psychogeriatr 2000;12:231-47.
10. Kornhuber J, Wellern M, Schoppmeyer K, Riederer P. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm 1994;43:91-104.
11. Müller WE, Mutschler E, Riederer P. Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia. Pharmacopsychiatry 1995;28:113-24.
12. th Collegium Internationale Neuro-Psychopharmacologicum (CINP), Paris, 20. bis 24. Juni 2004.
13. Reisberg B, Doody R, Stöffler A, Schmitt F, et al. Memantine in moderate-to-severe Alzheimer's disease. N Eng J Med 2003;348:1333-41.
14. Statistisches Bundesamt. Todesursachen in Deutschland 2003. In: Statistisches Bundesamt 2005, Fachserie 12, Reihe 4.
15. Tariot P, Farlow MR, Grossberg GT, Graham SM, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317-24.
16. Winblad B, Poritis N. Memantine in severe dementia: Results of the 9M-best study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999;14:135-46.